Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Nucl Med Biol. 2014 Aug 8;41(10):841–847. doi: 10.1016/j.nucmedbio.2014.08.002

Table I.

In Vitro Studies with 18F-fallypride on Spinal Cord Sections

Spinal Cord Sections1 SDH/WM DH/WM PC/WM VH/WM
Cervical 4.55 4.22 3.80 2.47
Thoracic 4.14 4.12 3.13 2.31
Lumbar 4.78 3.62 2.04 1.69
% Reduction2
Cervical −75.1% −76.5% −74.3% −67.8%
Thoracic −72% −74.3% −68.7% −61.2%
Lumbar −73.4% −64.3% −49.4% −48.3%
1

Spinal cord sections shown in Figure-2 (Total Binding, TB);

2

Reduction in binding by 10 μM sulpiride shown in Figure-2 (Nonspecific binding, NS);

SDH = superficial dorsal horn; DH = dorsal horn; PC = pars centralis; VH = ventral horn; WM = white matter (n=6).